NCT00371150

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 131 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.

Conditions

• Hepatitis B Infection

Interventions

Type	Name	Description
DRUG	Entecavir	Tablets, Oral, 0.5 mg, once daily, up to 52 weeks

Timeline

• Start date: 2006-11-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2006-09-01
• Last updated: 2012-04-16
• Results posted: 2012-04-16

Locations

27 sites across 5 countries: United States, Brazil, Mexico, Puerto Rico, South Africa